The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma.
 
Wesley Yip
No Relationships to Disclose
 
Jonathan Coleman
Travel, Accommodations, Expenses - Digital Angiography Reading Center (I)
Other Relationship - Steba Biotech
 
Nathan Colin Wong
No Relationships to Disclose
 
Daniel D. Sjoberg
Consulting or Advisory Role - OPKO Diagnostics
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Olympus
 
Guido Dalbagni
No Relationships to Disclose
 
S. Machele Donat
No Relationships to Disclose
 
Harry W. Herr
No Relationships to Disclose
 
Eugene J. Pietzak
Honoraria - UpToDate
Consulting or Advisory Role - Chugai Pharma; Janssen; Merck; QED Therapeutics
 
A. Ari Hakimi
No Relationships to Disclose
 
Kwanghee Kim
No Relationships to Disclose
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech; PAIGE.AI
 
Hebert Alberto Vargas
No Relationships to Disclose
 
Anoop M. Meraney
No Relationships to Disclose
 
Angelo Angelino Baccala
No Relationships to Disclose
 
Andrea B. Apolo
No Relationships to Disclose
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Min Yuen Teo
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - Clinical Care Options; EMD Serono; Intellisphere; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Adicet Bio; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck